[Gender-specific differences in the development of colorectal cancer in Lynch syndrome patients-A systematic review].
Geschlechtsspezifische Unterschiede in der Entwicklung kolorektaler Karzinome bei Lynch-Syndrom-Betroffenen – ein systematisches Review.
Age at disease onset
Cumulative risk
Gender
Genetics
Sex
Journal
Chirurgie (Heidelberg, Germany)
ISSN: 2731-698X
Titre abrégé: Chirurgie (Heidelb)
Pays: Germany
ID NLM: 9918383081906676
Informations de publication
Date de publication:
15 Aug 2024
15 Aug 2024
Historique:
accepted:
31
07
2024
medline:
15
8
2024
pubmed:
15
8
2024
entrez:
15
8
2024
Statut:
aheadofprint
Résumé
Lynch syndrome (LS) is the most frequent hereditary tumor syndrome and is associated with an increased risk of colorectal cancer (CRC). While gene-specific and age-specific differences are considered in patient surveillance, gender-specific risks in the development of CRC have been reported in many studies but are not consistently documented. This systematic review aims to investigate gender-specific differences in CRC development among LS patients. A systematic literature search following PRISMA 2020 guidelines was conducted in the PubMed, Ovid, The Cochrane Library and Web of Science databases. A total of 688 studies were screened, and 41 met the inclusion criteria. Men have a higher risk of CRC and develop CRC earlier compared to women. These findings indicate gender-specific differences in the risk of CRC among LS patients, although they do not currently justify separate surveillance strategies. HINTERGRUND: Das Lynch-Syndrom (LS) ist das häufigste erbliche Tumorsyndrom und mit einem erhöhten Risiko für kolorektale Karzinome (KRK) verbunden. Gen- und altersspezifische Unterschiede werden bei der Überwachung berücksichtigt, während geschlechtsspezifische Risiken in der Entwicklung eines KRK in vielen Studien berichtet, aber nicht einheitlich dokumentiert sind. Ziel dieser systematischen Übersichtsarbeit ist es, geschlechtsspezifische Unterschiede in der Entwicklung eines KRK bei LS-Betroffenen zu untersuchen. Eine systematische Literatursuche nach PRISMA 2020 wurde in den Datenbanken PubMed, Ovid, The Cochrane Library und Web of Science durchgeführt. 688 Studien wurden gesichtet, 41 erfüllten die Einschlusskriterien. Männer mit einem LS-Syndrom haben ein höheres Risiko für ein KRK und erkranken früher an einem KRK als Frauen. Die Ergebnisse weisen auf geschlechtsspezifische Unterschiede beim KRK-Risiko bei LS-Betroffenen hin, aus denen sich aber derzeit keine gesonderten Überwachungsstrategien ableiten lassen.
Sections du résumé
BACKGROUND
BACKGROUND
Lynch syndrome (LS) is the most frequent hereditary tumor syndrome and is associated with an increased risk of colorectal cancer (CRC). While gene-specific and age-specific differences are considered in patient surveillance, gender-specific risks in the development of CRC have been reported in many studies but are not consistently documented.
OBJECTIVE
OBJECTIVE
This systematic review aims to investigate gender-specific differences in CRC development among LS patients.
MATERIAL AND METHODS
METHODS
A systematic literature search following PRISMA 2020 guidelines was conducted in the PubMed, Ovid, The Cochrane Library and Web of Science databases. A total of 688 studies were screened, and 41 met the inclusion criteria.
RESULTS
RESULTS
Men have a higher risk of CRC and develop CRC earlier compared to women.
CONCLUSION
CONCLUSIONS
These findings indicate gender-specific differences in the risk of CRC among LS patients, although they do not currently justify separate surveillance strategies.
ZUSAMMENFASSUNG
UNASSIGNED
HINTERGRUND: Das Lynch-Syndrom (LS) ist das häufigste erbliche Tumorsyndrom und mit einem erhöhten Risiko für kolorektale Karzinome (KRK) verbunden. Gen- und altersspezifische Unterschiede werden bei der Überwachung berücksichtigt, während geschlechtsspezifische Risiken in der Entwicklung eines KRK in vielen Studien berichtet, aber nicht einheitlich dokumentiert sind.
FRAGESTELLUNG
UNASSIGNED
Ziel dieser systematischen Übersichtsarbeit ist es, geschlechtsspezifische Unterschiede in der Entwicklung eines KRK bei LS-Betroffenen zu untersuchen.
MATERIAL UND METHODEN
METHODS
Eine systematische Literatursuche nach PRISMA 2020 wurde in den Datenbanken PubMed, Ovid, The Cochrane Library und Web of Science durchgeführt. 688 Studien wurden gesichtet, 41 erfüllten die Einschlusskriterien.
ERGEBNISSE
UNASSIGNED
Männer mit einem LS-Syndrom haben ein höheres Risiko für ein KRK und erkranken früher an einem KRK als Frauen.
SCHLUSSFOLGERUNG
UNASSIGNED
Die Ergebnisse weisen auf geschlechtsspezifische Unterschiede beim KRK-Risiko bei LS-Betroffenen hin, aus denen sich aber derzeit keine gesonderten Überwachungsstrategien ableiten lassen.
Autres résumés
Type: Publisher
(ger)
HINTERGRUND: Das Lynch-Syndrom (LS) ist das häufigste erbliche Tumorsyndrom und mit einem erhöhten Risiko für kolorektale Karzinome (KRK) verbunden. Gen- und altersspezifische Unterschiede werden bei der Überwachung berücksichtigt, während geschlechtsspezifische Risiken in der Entwicklung eines KRK in vielen Studien berichtet, aber nicht einheitlich dokumentiert sind.
Identifiants
pubmed: 39145869
doi: 10.1007/s00104-024-02159-x
pii: 10.1007/s00104-024-02159-x
doi:
Types de publication
English Abstract
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Peltomäki P, Nyström M, Mecklin J‑P, Seppälä TT (2023) Lynch Syndrome Genetics and Clinical Implications. Gastroenterology 164(5):783–799. https://doi.org/10.1053/j.gastro.2022.08.058
doi: 10.1053/j.gastro.2022.08.058
pubmed: 36706841
Dominguez-Valentin M, Haupt S, Seppälä TT et al (2023) Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2023.101909
doi: 10.1016/j.eclinm.2023.101909
pubmed: 37181409
pmcid: 10166779
Haas S, Nattermann J, Hüneburg R (2023) Personalisierte Prävention und Früherkennung am Beispiel des Lynch-Syndroms. Onkologie 29(10):859–867. https://doi.org/10.1007/s00761-023-01360-7
doi: 10.1007/s00761-023-01360-7
Severin F, Stollenwerk B, Holinski-Feder E, Meyer E, Heinemann V, Giessen-Jung C, Rogowski W (2015) Economic evaluation of genetic screening for Lynch syndrome in Germany. Genet Med 17(10):765–773. https://doi.org/10.1038/gim.2014.190
doi: 10.1038/gim.2014.190
pubmed: 25569434
van Leerdam ME, Roos VH, van Hooft JE, Balaguer F, Dekker E, Kaminski MF, Latchford A, Neumann H, Ricciardiello L, Rupińska M, Saurin J‑C, Tanis PJ, Wagner A, Jover R, Pellisé M (2019) Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 51(11):1082–1093. https://doi.org/10.1055/a-1016-4977
doi: 10.1055/a-1016-4977
pubmed: 31597170
Schmiegel W, Buchberger B, Follmann M, Graeven U, Heinemann V, Langer T, Nothacker M, Porschen R, Rödel C, Rösch T, Schmitt W, Wesselmann S, Pox C (2017) S3-Leitlinie – Kolorektales Karzinom. Z Gastroenterol 55(12):1344–1498. https://doi.org/10.1055/s-0043-121106
doi: 10.1055/s-0043-121106
pubmed: 29212104
Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, Laurent-Puig P, Quirke P, Yoshino T, Taieb J, Martinelli E, Arnold D (2020) Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(10):1291–1305. https://doi.org/10.1016/j.annonc.2020.06.022
doi: 10.1016/j.annonc.2020.06.022
pubmed: 32702383
Engel C, Vasen HF, Seppala T et al (2018) No Difference in Colorectal Cancer Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch Syndrome Surveillance Policies. Gastroenterology. https://doi.org/10.1053/j.gastro.2018.07.030
doi: 10.1053/j.gastro.2018.07.030
pubmed: 30063918
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int J Surg 88:105906. https://doi.org/10.1016/j.ijsu.2021.105906
doi: 10.1016/j.ijsu.2021.105906
pubmed: 33789826
Clark J, Glasziou P, Del Mar C, Bannach-Brown A, Stehlik P, Scott AM (2020) A full systematic review was completed in 2 weeks using automation tools: a case study. J Clin Epidemiol 121:81–90. https://doi.org/10.1016/j.jclinepi.2020.01.008
doi: 10.1016/j.jclinepi.2020.01.008
pubmed: 32004673
ASReview LAB developers (2023) ASReview LAB—A tool for AI-assisted systematic reviews. Zenodo
Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, La Chapelle A, Peltomki P, Mecklin J‑P, Jrvinen HJ (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Intl Journal of Cancer 81(2):214–218. https://doi.org/10.1002/(SICI)1097-0215(19990412)81:2
doi: 10.1002/(SICI)1097-0215(19990412)81:2
Alarcon F, Lasset C, Carayol J, Bonadona V, Perdry H, Desseigne F, Wang Q, Bonaïti-Pellié C (2007) Estimating cancer risk in HNPCC by the GRL method. Eur J Hum Genet 15(8):831–836. https://doi.org/10.1038/sj.ejhg.5201843
doi: 10.1038/sj.ejhg.5201843
pubmed: 17473834
Alvarez K, Orellana P, La Fuente M, Canales T, Pinto E, Heine C, Solar B, Hurtado C, Moller P, Kronberg U, Zarate JA, Dominguez-Valentin M, Lopez-Kostner F (2020) Spectrum and Frequency of Tumors, Cancer Risk and Survival in Chilean Families with Lynch Syndrome: Experience of the Implementation of a Registry. JCM. https://doi.org/10.3390/jcm9061861
doi: 10.3390/jcm9061861
pubmed: 33271929
pmcid: 7761005
Baglietto L, Lindor NM, Dowty JG et al (2010) Risks of Lynch Syndrome Cancers for MSH6 Mutation Carriers. JNCIJ. https://doi.org/10.1093/jnci/djp473
doi: 10.1093/jnci/djp473
Barrow E, Alduaij W, Robinson L, Shenton A, Clancy T, Lalloo F, Hill J, Evans DG (2008) Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clin Genet 74(3):233–242. https://doi.org/10.1111/j.1399-0004.2008.01035.x
doi: 10.1111/j.1399-0004.2008.01035.x
pubmed: 18554281
Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, Huiart L, Longy M, Guimbaud R, Buecher B, Bignon Y‑J, Caron O, Colas C, Noguès C, Lejeune-Dumoulin S, Olivier-Faivre L, Polycarpe-Osaer F, Nguyen TD, Desseigne F, Saurin J‑C, Berthet P, Leroux D, Duffour J, Manouvrier S, Frébourg T, Sobol H, Lasset C, Bonaïti-Pellié C (2011) Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 305(22):2304–2310. https://doi.org/10.1001/jama.2011.743
doi: 10.1001/jama.2011.743
pubmed: 21642682
Broeke SW, van der Klift HM, Tops CMJ et al (2018) Cancer Risks for PMS2-Associated Lynch Syndrome. J Clin Oncol 36(29):2961–2968. https://doi.org/10.1200/JCO.2018.78.4777
doi: 10.1200/JCO.2018.78.4777
pubmed: 30161022
pmcid: 6349460
Cederquist K, Emanuelsson M, Wiklund F, Golovleva I, Palmqvist R, Grönberg H (2005) Two Swedish founder MSH6 mutations, one nonsense and one missense, conferring high cumulative risk of Lynch syndrome. Clin Genet. https://doi.org/10.1111/j.1399-0004.2005.00537.x
doi: 10.1111/j.1399-0004.2005.00537.x
pubmed: 16283884
Choi Y‑H, Cotterchio M, McKeown-Eyssen G, Neerav M, Bapat B, Boyd K, Gallinger S, McLaughlin J, Aronson M, Briollais L (2009) Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario. Hered Cancer Clin Pract. https://doi.org/10.1186/1897-4287-7-14
doi: 10.1186/1897-4287-7-14
pubmed: 19863818
pmcid: 2775728
Dominguez-Valentin M, Sampson JR, Seppala TT et al (2020) Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med. https://doi.org/10.1038/s41436-019-0596-9
doi: 10.1038/s41436-019-0596-9
pubmed: 33257847
pmcid: 8026395
Dowty JG, Win AK, Buchanan DD, Lindor NM, Macrae FA, Clendenning M, Antill YC, Thibodeau SN, Casey G, Gallinger S, Le Marchand L, Newcomb PA, Haile RW, Young GP, James PA, Giles GG, Gunawardena SR, Leggett BA, Gattas M, Boussioutas A, Ahnen DJ, Baron JA, Parry S, Goldblatt J, Young JP, Hopper JL, Jenkins MA (2013) Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat 34(3):490–497. https://doi.org/10.1002/humu.22262
doi: 10.1002/humu.22262
pubmed: 23255516
Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, Liu B, Kinzler KW, Vogelstein B (1997) Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6(1):105–110. https://doi.org/10.1093/hmg/6.1.105
doi: 10.1093/hmg/6.1.105
pubmed: 9002677
Edelstein DL, Axilbund J, Baxter M, Hylind LM, Romans K, Griffin CA, Cruz-Correa M, Giardiello FM (2011) Rapid development of colorectal neoplasia in patients with Lynch syndrome. Clin Gastroenterol Hepatol. https://doi.org/10.1016/j.cgh.2010.10.033
doi: 10.1016/j.cgh.2010.10.033
pubmed: 21070872
Froggatt NJ, Green J, Brassett C, Evans DG, Bishop DT, Kolodner R, Maher ER (1999) A common MSH2 mutation in English and North American HNPCC families: origin, phenotypic expression, and sex specific differences in colorectal cancer. J Med Genet 36(2)
Green J, O’Driscoll M, Barnes A, Maher ER, Bridge P, Shields K, Parfrey PS (2002) Impact of gender and parent of origin on the phenotypic expression of hereditary nonpolyposis colorectal cancer in a large Newfoundland kindred with a common MSH2 mutation. Dis Colon Rectum. https://doi.org/10.1007/s10350-004-6397-4
doi: 10.1007/s10350-004-6397-4
pubmed: 12352241
Guindalini RSC, Win AK, Gulden C, Lindor NM, Newcomb PA, Haile RW, Raymond V, Stoffel E, Hall M, Llor X, Ukaegbu CI, Solomon I, Weitzel J, Kalady M, Blanco A, Terdiman J, Shuttlesworth GA, Lynch PM, Hampel H, Lynch HT, Jenkins MA, Olopade OI, Kupfer SS (2015) Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome. Gastroenterology. https://doi.org/10.1053/j.gastro.2015.07.052
doi: 10.1053/j.gastro.2015.07.052
pubmed: 26248088
Hendriks YMC, Wagner A, Morreau H, Menko F, Stormorken A, Quehenberger F, Sandkuijl L, Møller P, Genuardi M, van Houwelingen H, Tops C, van Puijenbroek M, Verkuijlen P, Kenter G, van Mil A, Meijers-Heijboer H, Tan GB, Breuning MH, Fodde R, Wijnen JT, Bröcker-Vriends AHJT, Vasen H (2004) Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 127(1):17–25. https://doi.org/10.1053/j.gastro.2004.03.068
doi: 10.1053/j.gastro.2004.03.068
pubmed: 15236168
Jenkins MA, Baglietto L, Dowty JG, van Vliet CM, Smith L, Mead LJ, Macrae FA, John Jass Hopper Southey StDJGGGJLMC (2006) Cancer risks for mismatch repair gene mutation carriers: A population-based early onset case-family study. Clin Gastroenterol Hepatol. https://doi.org/10.1016/j.cgh.2006.01.002
doi: 10.1016/j.cgh.2006.01.002
pubmed: 16616355
Kamiza AB, Wang W‑C, You J‑F, Tang R, Chien H‑T, Lai C‑H, Chiu L‑L, Lo T‑P, Hung K‑Y, Hsiung CA, Yeh C‑C (2021) Cumulative risks of colorectal cancer in Han Chinese patients with Lynch syndrome in Taiwan. Sci Rep. https://doi.org/10.1038/s41598-021-88289-2
doi: 10.1038/s41598-021-88289-2
pubmed: 33903664
pmcid: 8076276
Kopciuk KA, Choi Y‑H, Parkhomenko E, Parfrey P, McLaughlin J, Green J, Briollais L (2009) Penetrance of HNPCC-related cancers in a retrolective cohort of 12 large Newfoundland families carrying a MSH2 founder mutation: an evaluation using modified segregation models. Hered Cancer Clin Pract. https://doi.org/10.1186/1897-4287-7-16
doi: 10.1186/1897-4287-7-16
pubmed: 19863818
pmcid: 2775728
Lin KM, Shashidharan M, Thorson AG, Ternent CA, Blatchford GJ, Christensen MA, Watson P, Lemon SJ, Franklin B, Karr B, Lynch J, Lynch HT (1998) Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary nonpolyposis colorectal cancer. J Gastrointest Surg. https://doi.org/10.1016/S1091-255X(98)80105-4
doi: 10.1016/S1091-255X(98)80105-4
pubmed: 9841970
Moller P, Seppala T, Bernstein I et al (2017) Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut. https://doi.org/10.1136/gutjnl-2015-309675
doi: 10.1136/gutjnl-2015-309675
pubmed: 28754778
Moller P, Seppala TT, Bernstein I et al (2018) Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut. https://doi.org/10.1136/gutjnl-2017-314057
doi: 10.1136/gutjnl-2017-314057
pubmed: 28754778
Møller P, Seppälä T, Dowty JG et al (2022) Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective lynch syndrome database and the international mismatch repair consortium. Hered Cancer Clin Pract 20(1):36. https://doi.org/10.1186/s13053-022-00241-1
doi: 10.1186/s13053-022-00241-1
pubmed: 36182917
pmcid: 9526951
Quehenberger F, Vasen HFA, van Houwelingen HC (2005) Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet 42(6):491–496. https://doi.org/10.1136/jmg.2004.024299
doi: 10.1136/jmg.2004.024299
pubmed: 15937084
pmcid: 1736072
Ramsoekh D, Wagner A, van Leerdam ME, Dooijes D, Tops CM, Steyerberg EW, Kuipers EJ (2009) Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management. Hered Cancer Clin Pract 7(1):17. https://doi.org/10.1186/1897-4287-7-17
doi: 10.1186/1897-4287-7-17
pubmed: 20028567
pmcid: 2804564
Rodrigues RV, Claro I, Lage P, Rosa I, Ferreira S, Da Silva JP, Pereira AD (2018) Colorectal cancer surveillance in Portuguese families with lynch syndrome: a cohort study. Int J Colorectal Dis. https://doi.org/10.1007/s00384-018-3002-1
doi: 10.1007/s00384-018-3002-1
Stoffel E, Mukherjee B, Raymond VM, Tayob N, Kastrinos F, Sparr J, Wang F, Bandipalliam P, Syngal S, Gruber SB (2009) Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 137(5):1621–1627. https://doi.org/10.1053/j.gastro.2009.07.039
doi: 10.1053/j.gastro.2009.07.039
pubmed: 19622357
Stuckless S, Parfrey PS, Woods MO, Cox J, Fitzgerald GW, Green JS, Green RC (2007) The phenotypic expression of three MSH2 mutations in large Newfoundland families with Lynch syndrome. Fam Cancer. https://doi.org/10.1007/s10689-006-0014-8
doi: 10.1007/s10689-006-0014-8
pubmed: 17039271
Suerink M, Rodriguez-Girondo M, van der Klift HM et al (2019) An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome. Genet Med. https://doi.org/10.1038/s41436-019-0577-z
doi: 10.1038/s41436-019-0577-z
pubmed: 31204389
Talseth-Palmer BA, McPhillips M, Groombridge C, Spigelman A, Scott RJ (2010) MSH6 and PMS2 mutation positive Australian Lynch syndrome families: novel mutations, cancer risk and age of diagnosis of colorectal cancer. Hered Cancer Clin Pract 8(1):5. https://doi.org/10.1186/1897-4287-8-5
doi: 10.1186/1897-4287-8-5
pubmed: 20487569
pmcid: 2890527
Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, Taal BG, Moller P, Wijnen JT (2001) MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol. https://doi.org/10.1200/JCO.2001.19.20.4074
doi: 10.1200/JCO.2001.19.20.4074
pubmed: 11600610
Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G, Nagengast FM, Meijers-Heijboer EH, Bertario L, Varesco L, Bisgaard ML, Mohr J, Fodde R, Khan PM (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110(4):1020–1027. https://doi.org/10.1053/gast.1996.v110.pm8612988
doi: 10.1053/gast.1996.v110.pm8612988
pubmed: 8612988
Bucksch K, Zachariae S, Ahadova A, Aretz S, Buttner R, Goergens H, Holinski-Feder E, Hueneburg R, Kloor M, Doeberitz MK, Ladigan-Badura S, Moeslein G, Morak M, Nattermann J, Nguyen HP, Perne C, Redler S, Schmetz A, Steinke-Lange V, Surowy H, Vangala DB, Weitz J, Loeffler M, Engel C, Consortium Familial Intesti G (2022) Adenoma and colorectal cancer risks in Lynch syndrome, Lynch-like syndrome and familial colorectal cancer type X. Intl Journal of Cancer. https://doi.org/10.1002/ijc.33790
doi: 10.1002/ijc.33790
Jenkins MA (2021) Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. Lancet Oncol. https://doi.org/10.1016/S1470-2045(21)00189-3
doi: 10.1016/S1470-2045(21)00189-3
pubmed: 34000245
pmcid: 8934577
Hampel H, Stephens JA, Pukkala E, Sankila R, La Aaltonen, Mecklin JP, La Chapelle A (2005) Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: Later age of onset. Gastroenterology. https://doi.org/10.1053/j.gastro.2005.05.011
doi: 10.1053/j.gastro.2005.05.011
pubmed: 16083711
Parc Y, Boisson C, Thomas G, Olschwang S (2003) Cancer risk in 348 French MSH2 or MLH1 gene carriers. J Med Genet. https://doi.org/10.1136/jmg.40.3.208
doi: 10.1136/jmg.40.3.208
pubmed: 12624141
pmcid: 1735402
Biller LH, Horiguchi M, Uno H, Ukaegbu C, Syngal S, Yurgelun MB (2021) Familial Burden and Other Clinical Factors Associated With Various Types of Cancer in Individuals With Lynch Syndrome. Gastroenterology. https://doi.org/10.1053/j.gastro.2021.03.039
doi: 10.1053/j.gastro.2021.03.039
pubmed: 33794268
Jamizadeh N, Bernstedt SW, Haxhijaj A, Andreasson A, Bjork J, Forsberg A, Backman A‑S (2023) Endoscopic surveillance of Lynch syndrome at a highly specialized center in Sweden: An observational study of interval colorectal cancer and individual risk factors. Front Oncol. https://doi.org/10.3389/fonc.2023.1127707
doi: 10.3389/fonc.2023.1127707
pubmed: 36890827
pmcid: 9987586
Del Carmen G, Reyes-Uribe L, Goyco D, Evans K, Bowen CM, Kinnison JL, Sepeda VO, Weber DM, Moskowitz J, Mork ME, Thirumurthi S, Lynch PM, Rodriguez-Bigas MA, Taggart MW, You YN, Vilar E (2023) Colorectal surveillance outcomes from an institutional longitudinal cohort of lynch syndrome carriers. Front Oncol. https://doi.org/10.3389/fonc.2023.1146825
doi: 10.3389/fonc.2023.1146825
pubmed: 37168379
pmcid: 10164917
Hüneburg R, Aretz S, Büttner R, Daum S, Engel C, Fechner G, Habermann JK, Heling D, Hoffmann K, Holinski-Feder E, Kloor M, Knebel-Döberitz M, Loeffler M, Möslein G, Perne C, Redler S, Rieß O, Schmiegel W, Seufferlein T, Siebers-Renelt U, Steinke-Lange V, Tecklenburg J, Vangala D, Vilz T, Weitz J, Wiedenmann B, Strassburg CP, Nattermann J (2019) Current recommendations for surveillance, risk reduction and therapy in Lynch syndrome patients. Z Gastroenterol. https://doi.org/10.1055/a-1008-9827
doi: 10.1055/a-1008-9827
pubmed: 31739377
National Comprehensive Cancer Network (2017) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). (No Title)
Seppälä TT, Latchford A, Negoi I, Sampaio Soares A, Jimenez-Rodriguez R, Sánchez-Guillén L, Evans DG, Ryan N, Crosbie EJ, Dominguez-Valentin M, Burn J, Kloor M, Knebel Doeberitz M, van Duijnhoven FJB, Quirke P, Sampson JR, Møller P, Möslein G (2021) European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender. Br J Surg. https://doi.org/10.1002/bjs.11902
doi: 10.1002/bjs.11902
pubmed: 34043773
pmcid: 10364896
Umar A, Boland CR, Terdiman JP, Syngal S, La Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HFA, Hawk ET, Barrett JC, Freedman AN, Freedman AN (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. JNCIJ 96(4):261–268. https://doi.org/10.1093/jnci/djh034
doi: 10.1093/jnci/djh034